BRPI0416596A - dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade - Google Patents

dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade

Info

Publication number
BRPI0416596A
BRPI0416596A BRPI0416596-9A BRPI0416596A BRPI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A
Authority
BR
Brazil
Prior art keywords
mtp inhibitor
solid amorphous
obesity treatment
amorphous dispersions
solid
Prior art date
Application number
BRPI0416596-9A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0416596A publication Critical patent/BRPI0416596A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
BRPI0416596-9A 2003-11-14 2004-11-01 dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade BRPI0416596A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
PCT/IB2004/003581 WO2005046644A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Publications (1)

Publication Number Publication Date
BRPI0416596A true BRPI0416596A (pt) 2007-01-30

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416596-9A BRPI0416596A (pt) 2003-11-14 2004-11-01 dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade

Country Status (16)

Country Link
US (1) US20080293801A1 (enExample)
EP (1) EP1696887A1 (enExample)
JP (1) JP2007511500A (enExample)
KR (1) KR20060096076A (enExample)
CN (1) CN1878538A (enExample)
AR (1) AR048206A1 (enExample)
AU (1) AU2004289110A1 (enExample)
BR (1) BRPI0416596A (enExample)
CA (1) CA2545443A1 (enExample)
CO (1) CO5690536A2 (enExample)
IL (1) IL175372A0 (enExample)
MX (1) MXPA06005489A (enExample)
NO (1) NO20062778L (enExample)
NZ (1) NZ546677A (enExample)
TW (1) TW200515909A (enExample)
WO (1) WO2005046644A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631694A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
EP2522657B1 (en) 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
TNSN03146A1 (fr) * 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
JP2007511500A (ja) 2007-05-10
IL175372A0 (en) 2006-09-05
US20080293801A1 (en) 2008-11-27
AU2004289110A1 (en) 2005-05-26
TW200515909A (en) 2005-05-16
CN1878538A (zh) 2006-12-13
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
CA2545443A1 (en) 2005-05-26
KR20060096076A (ko) 2006-09-05
WO2005046644A1 (en) 2005-05-26
AR048206A1 (es) 2006-04-12
CO5690536A2 (es) 2006-10-31
NO20062778L (no) 2006-08-14
NZ546677A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
BR0307277A (pt) Composições farmacêuticas de inibidores da proteìna de transferencia do éster de colesterilo
PL1861365T3 (pl) N-sulfonylopirole i ich zastosowanie jako inhibitorów deacetylazy histonów
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
DE60317677D1 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EA200300073A1 (ru) Фармацевтические композиции ингибиторов белка переноса холестериловых эфиров
BR0317872A (pt) Medicamentos antiinflamatórios
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
EP1933881A4 (en) SOLID POLYMER DISPENSING COMPOSITIONS AND APPLICATION METHOD THEREFOR
CA2383135A1 (en) Method of identifying properties of substance with respect to human prostaglandin d2 receptors
BR0309969A (pt) Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos
MX2010001657A (es) Reguladores de mmp-9 y usos de los mismos.
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
BRPI0416596A (pt) dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade
ATE516052T1 (de) Zusammensetzungen für knochenzemente enthaltend eine nichtpolymerisierbare organoiodverbindung
BR0316206A (pt) Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos
BR0315554A (pt) Dispersões poliméricas com alta estabilidade e processos para sua preparação
BRPI0515776A (pt) auxiliares de retenção e drenagem
DE60233111D1 (de) Glucocorticoid-rezeptoren-modulatoren
BRPI0404824A (pt) Processos para preparar uma composição de polìmero, um polìmero multifuncional, e uma composição multifuncional para modificação de cabelos
ATE503774T1 (de) Photohärtbare michaeladditionspolymere
BRPI0409730A (pt) tratamento da incontinência
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung
DE602006017837D1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
CR9008A (es) Nuevo procedimiento y compuestos intermedios de preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenilmetilsulfonamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.